Moberg Pharma AB has appointed Helena Jansson as chief business officer and deputy CEO, and Vaidrius Navikas as chief medical officer to strengthen the organisation amid product launches, regulatory processes and collaborations. Christina Erixon, senior director product management, will step down from the management team and remain a part-time consultant. Ms Jansson has more than 30 years of experience in life sciences, leading global marketing, sales and commercial operations. Most recently, she was managing director at Palette Life Sciences.
Dr Navikas, with a PhD in neuroimmunology, beings more than 30 years in pharmaceutical development and commercialisation. He was most recently head of global medical affairs at H. Lundbeck A/S. Moberg Pharma’s drug MOB-015 for onychomycosis (nail fungus) has market approval in 14 countries and is sold currently in Sweden and Norway. The company expanded its collaboration with Karo Healthcare earlier in 2026.
Moberg Pharma announced the appointments on 11 August 2026.
Copyright 2026 Evernow Publishing Ltd.